vs
Orion Properties Inc.(ONL)与RECURSION PHARMACEUTICALS, INC.(RXRX)财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Orion Properties Inc.的1.0倍($35.5M vs $35.2M),Orion Properties Inc.净利率更高(-101.7% vs -304.2%,领先202.6%),RECURSION PHARMACEUTICALS, INC.同比增速更快(681.7% vs -8.2%),过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高(60.5% vs -13.6%)
Recursion Pharmaceuticals是一家临床阶段生物技术企业,依托人工智能技术和高通量生物实验体系,开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法,核心市场覆盖北美,与全球多家生物制药企业合作推进在研管线落地。
ONL vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.0倍
$35.2M
营收增速更快
RXRX
高出689.9%
-8.2%
净利率更高
ONL
高出202.6%
-304.2%
两年增速更快
RXRX
近两年复合增速
-13.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $35.2M | $35.5M |
| 净利润 | $-35.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -101.5% | -304.8% |
| 净利率 | -101.7% | -304.2% |
| 营收同比 | -8.2% | 681.7% |
| 净利润同比 | -9.3% | 39.6% |
| 每股收益(稀释后) | $-0.63 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ONL
RXRX
| Q4 25 | $35.2M | $35.5M | ||
| Q3 25 | $37.1M | $5.2M | ||
| Q2 25 | $37.3M | $19.2M | ||
| Q1 25 | $38.0M | $14.7M | ||
| Q4 24 | $38.4M | $4.5M | ||
| Q3 24 | $39.2M | $26.1M | ||
| Q2 24 | $40.1M | $14.4M | ||
| Q1 24 | $47.2M | $13.8M |
净利润
ONL
RXRX
| Q4 25 | $-35.8M | $-108.1M | ||
| Q3 25 | $-69.0M | $-162.3M | ||
| Q2 25 | $-25.1M | $-171.9M | ||
| Q1 25 | $-9.4M | $-202.5M | ||
| Q4 24 | $-32.8M | $-178.9M | ||
| Q3 24 | $-10.2M | $-95.8M | ||
| Q2 24 | $-33.8M | $-97.5M | ||
| Q1 24 | $-26.2M | $-91.4M |
毛利率
ONL
RXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率
ONL
RXRX
| Q4 25 | -101.5% | -304.8% | ||
| Q3 25 | -185.8% | -3327.6% | ||
| Q2 25 | -67.1% | -916.8% | ||
| Q1 25 | -24.4% | -1297.9% | ||
| Q4 24 | -85.4% | -4042.4% | ||
| Q3 24 | -25.9% | -377.1% | ||
| Q2 24 | -84.1% | -697.4% | ||
| Q1 24 | -55.4% | -698.4% |
净利率
ONL
RXRX
| Q4 25 | -101.7% | -304.2% | ||
| Q3 25 | -186.0% | -3135.3% | ||
| Q2 25 | -67.3% | -894.2% | ||
| Q1 25 | -24.6% | -1373.3% | ||
| Q4 24 | -85.4% | -3935.5% | ||
| Q3 24 | -26.1% | -367.5% | ||
| Q2 24 | -84.2% | -676.6% | ||
| Q1 24 | -55.6% | -662.4% |
每股收益(稀释后)
ONL
RXRX
| Q4 25 | $-0.63 | $-0.17 | ||
| Q3 25 | $-1.23 | $-0.36 | ||
| Q2 25 | $-0.45 | $-0.41 | ||
| Q1 25 | $-0.17 | $-0.50 | ||
| Q4 24 | $-0.59 | $-0.56 | ||
| Q3 24 | $-0.18 | $-0.34 | ||
| Q2 24 | $-0.60 | $-0.40 | ||
| Q1 24 | $-0.47 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $22.4M | $743.3M |
| 总债务越低越好 | $465.0M | $9.6M |
| 股东权益账面价值 | $623.2M | $1.1B |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.75× | 0.01× |
8季度趋势,按日历期对齐
现金及短期投资
ONL
RXRX
| Q4 25 | $22.4M | $743.3M | ||
| Q3 25 | $32.6M | $659.8M | ||
| Q2 25 | $17.4M | $525.1M | ||
| Q1 25 | $9.4M | $500.5M | ||
| Q4 24 | $15.6M | $594.4M | ||
| Q3 24 | $16.6M | $427.6M | ||
| Q2 24 | $24.2M | $474.3M | ||
| Q1 24 | $23.6M | $296.3M |
总债务
ONL
RXRX
| Q4 25 | $465.0M | $9.6M | ||
| Q3 25 | $483.0M | $11.9M | ||
| Q2 25 | $483.0M | $14.2M | ||
| Q1 25 | $505.0M | $16.4M | ||
| Q4 24 | $492.0M | $19.0M | ||
| Q3 24 | $485.0M | $20.5M | ||
| Q2 24 | $462.0M | $22.9M | ||
| Q1 24 | $471.0M | — |
股东权益
ONL
RXRX
| Q4 25 | $623.2M | $1.1B | ||
| Q3 25 | $658.8M | $1.0B | ||
| Q2 25 | $728.0M | $919.1M | ||
| Q1 25 | $753.5M | $933.9M | ||
| Q4 24 | $763.9M | $1.0B | ||
| Q3 24 | $800.9M | $524.6M | ||
| Q2 24 | $816.1M | $584.4M | ||
| Q1 24 | $854.6M | $401.2M |
总资产
ONL
RXRX
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.4B | $726.5M | ||
| Q2 24 | $1.3B | $775.9M | ||
| Q1 24 | $1.4B | $557.8M |
负债/权益比
ONL
RXRX
| Q4 25 | 0.75× | 0.01× | ||
| Q3 25 | 0.73× | 0.01× | ||
| Q2 25 | 0.66× | 0.02× | ||
| Q1 25 | 0.67× | 0.02× | ||
| Q4 24 | 0.64× | 0.02× | ||
| Q3 24 | 0.61× | 0.04× | ||
| Q2 24 | 0.57× | 0.04× | ||
| Q1 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $23.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势,按日历期对齐
经营现金流
ONL
RXRX
| Q4 25 | $23.6M | $-46.1M | ||
| Q3 25 | $5.7M | $-117.4M | ||
| Q2 25 | $11.6M | $-76.4M | ||
| Q1 25 | $-2.2M | $-132.0M | ||
| Q4 24 | $54.3M | $-115.4M | ||
| Q3 24 | $13.8M | $-59.2M | ||
| Q2 24 | $17.0M | $-82.2M | ||
| Q1 24 | $11.0M | $-102.3M |
自由现金流
ONL
RXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率
ONL
RXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度
ONL
RXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图